Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Lancet (London, England) • Vol. 393, Issue 10188 • 2019
Novel Non-biologic Targets for Inflammatory Bowel Disease.
Current gastroenterology reports • Vol. 21, Issue 5 • 2019
Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists.
Frontiers in pharmacology • Vol. 10 • 2019
Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.
Clinical pharmacology in drug development • Vol. 8, Issue 2 • 2019
